Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M McShane

Showing results (11-20 of 159) with videos related to

Pageof 16
Sort By:
Statistics in Medicine|September 11, 2008
A class comparison method with filtering-enhanced variable selection for high-dimensional data setsLara Lusa, Edward L Korn, Lisa M McShane
JAMA Oncology|May 12, 2017
Myeloma Minimal Residual Disease and SurrogacyRichard F Little, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute|January 16, 2010
Randomized clinical trials with biomarkers: design issuesBoris Freidlin, Lisa M McShane, Edward L Korn
Science Translational Medicine|March 29, 2013
Statistical challenges in the evaluation of treatments for small patient populationsEdward L Korn, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute|July 21, 2005
Identification of clinically useful cancer prognostic factors: what are we missing?Lisa M McShane, Douglas G Altman, Willi Sauerbrei
British Journal of Cancer|December 8, 2022
REMARK guidelines for tumour biomarker study reporting: a remarkable historyDaniel F Hayes, Willi Sauerbrei, Lisa M McShane
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|April 26, 2017
Importance of the distinction between quality of methodology and quality of reportingDouglas G Altman, Willi Sauerbrei, Lisa M McShane
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Effective incorporation of biomarkers into phase II trialsLisa M McShane, Sally Hunsberger, Alex A Adjei
The New England Journal of Medicine|February 19, 2025
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast CancerAntonio C Wolff, Lisa M McShane, Kimberly H Allison
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Pageof 16

Showing results (11-20 of 159) with videos related to

Sort By:
Pageof 16
Statistics in Medicine|September 11, 2008
A class comparison method with filtering-enhanced variable selection for high-dimensional data setsLara Lusa, Edward L Korn, Lisa M McShane
JAMA Oncology|May 12, 2017
Myeloma Minimal Residual Disease and SurrogacyRichard F Little, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute|January 16, 2010
Randomized clinical trials with biomarkers: design issuesBoris Freidlin, Lisa M McShane, Edward L Korn
Science Translational Medicine|March 29, 2013
Statistical challenges in the evaluation of treatments for small patient populationsEdward L Korn, Lisa M McShane, Boris Freidlin
Journal of the National Cancer Institute|July 21, 2005
Identification of clinically useful cancer prognostic factors: what are we missing?Lisa M McShane, Douglas G Altman, Willi Sauerbrei
British Journal of Cancer|December 8, 2022
REMARK guidelines for tumour biomarker study reporting: a remarkable historyDaniel F Hayes, Willi Sauerbrei, Lisa M McShane
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|April 26, 2017
Importance of the distinction between quality of methodology and quality of reportingDouglas G Altman, Willi Sauerbrei, Lisa M McShane
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Effective incorporation of biomarkers into phase II trialsLisa M McShane, Sally Hunsberger, Alex A Adjei
The New England Journal of Medicine|February 19, 2025
Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast CancerAntonio C Wolff, Lisa M McShane, Kimberly H Allison
Biostatistics (Oxford, England)|June 22, 2017
Discussion: The role, position, and function of the FDA-The past, present, and futureThomas R Fleming, David L Demets, Lisa M McShane
Pageof 16